Europe Branded Generics Market Share Analysis Report, 2023-2032
The europe branded generics market size accounted for USD 49.1 billion in 2022 and is estimated to achieve a market size of USD 80.82 billion by 2032, growing at a CAGR of 5.11% from 2023 to 2032.
Key Pointers:
Report Scope of the Europe branded generics Market
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 51.61 Billion |
|
Market Size by 2032 |
USD 80.82 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 5.11% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Drug class, Application, Route of administration, Distribution channel |
|
Key companies profiled |
Teva Pharmaceutical Industries Ltd; Lupin; Sanofi; Sun Pharmaceutical Industries, Ltd.; Dr. Reddy’s Laboratories Ltd; Endo International plc.; GlaxoSmithKline plc.; Wockhardt; Viatris, Inc.; Apotex, Inc. |
The rising prevalence of chronic diseases across the region is expected to contribute to market growth. The increasing burden of infectious & noninfectious diseases coupled with the growing geriatric population, which is more susceptible to chronic diseases, such as diabetes, hypertension, and obesity, is expected to positively impact market growth. In 2021, there were around 2.2 million people affected with HIV in WHO Europe Region, and around 57.0% of the newly diagnosed patients were from the Russian Federation. Competitive rivalry in the Europe branded generics market is likely to be high due to the various strategies adopted by the key players such as merger & acquisition and expansion of the business to strengthen their position in the market. Many established companies are engaged in the development of a generic version of branded drugs.
The prevalence of diabetes is growing rapidly in EU countries. According to WHO data for 2022, diabetes affects around 10%-20% of the population in member states of WHO European Region, which is increasing among all age groups. In 2022, a survey by WHO also reported a high prevalence of childhood obesity in Europe, stating that one in three children is overweight and obese. Thus, the growing prevalence of the disease is expected to propel Europe branded generics market.
The buyer of branded generic products include pharmacies, wholesalers, mail-order distributors, group purchasing organizations, and hospitals. Due to buyer’s enhanced capacity to negotiate competitive acquisition costs and ability to maximize their profits, market is witnessing competition based simply on cost and ability to supply medicines. Individual manufacturers have minimal control above the overall drug market pricing, consequently, increasing the bargaining power of the buyers.
The flexibility, comfort, and accessibility provided by online purchases of branded generic drugs are the major factors driving the segment. In addition, the discounts provided by online pharmacies attract patients to buy drugs online, which are also projected to fuel Europe branded generics market. However, the sale of prescription medicines on online platforms is prohibited, with the sale of nonprescription-based medicines being the smallest/least, which is contributing to the low share of online pharmacies in the branded generics market.
The UK has a high penetration of generics (approximately 70.0% by volume), low entry barriers, and relatively simplified entry requirements. However, sustaining in the UK market can be difficult for the branded generics players, as there is high dominance of unbranded generics. This impedes the opportunity to differentiate by company brand or product; thus, manufacturers are mainly dependent on pricing. Moreover, physicians are not mandated to prescribe according to INN in the UK.
The government is focusing on reducing healthcare expenditure by changing pricing policies. According to a report on new pricing models for generic medicines, around 70.0% of the generic products accounted for the total medicines dispensed in Europe. The pricing of generic products is affected by the significant consolidation of current pricing policies in Europe. For example, external reference pricing, tendering, short-term cost reduction measures (such as ad hoc price cuts), and payback has resulted in a significant decline in the prices of some off-patent medicines. Such policies are anticipated to increase competition and result in price erosion. These changes in traditional policies may leverage increased negotiation for the customers and additional pricing pressure which will restrain the branded generics market.
Europe branded generics Market Segmentation
| By Drug Class | By Application | By Route of Administration | By Distribution Channel |
|
Alkylating Agents Antimetabolites Hormones Anti-hypertensive & Lipid lowering drugs Anti-depressants Anti-psychotics Anti-epileptics Others |
Oncology Cardiovascular Diseases Neurological Diseases Gastrointestinal Diseases Dermatological diseases Acute and Chronic Pain Others
|
Topical Oral Parenteral Others |
Hospital Pharmacy Retail Pharmacy Online Pharmacy & Others |
Chapter 1 Methodology and Scope
1.1 Market segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.6 List of Primary Sources
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market
3.1.1 Europe Branded Generics Market
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Landscape
3.4 Europe Branded Generics Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Patent expiry of branded products
3.4.1.2 Increasing marketing approval and launch of branded generic products
3.4.1.3 Increasing disease burden and rising geriatric population
3.4.2 Market Restraint Analysis
3.4.2.1 Pricing pressure
3.4.3 Market Opportunity Analysis
3.4.3.1 Government initiatives promoting usage of generics
3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
Chapter 4 Europe Branded Generics Market - Segment Analysis, By Drug Class, 2020 - 2032
4.1 Europe Branded Generics Market: Drug Class Movement Analysis
4.2 Alkylating Agents
4.2.1 Alkylating Agents Market Estimates and Forecast, 2020 - 2032
4.3 Antimetabolites
4.3.1 Antimetabolites Market Estimates and Forecasts, 2020 - 2032
4.4 Hormones
4.4.1 Hormones Market Estimates and Forecasts, 2020 - 2032
4.5 Anti-hypertensive & Lipid lowering drugs
4.5.1 Anti-hypertensive & lipid lowering drugs market estimates and forecasts, 2020 - 2032
4.6 Anti-depressants
4.6.1 Anti-depressants Market Estimates and Forecasts, 2020 - 2032
4.7 Anti-psychotics
4.7.1 Anti-Psychotics Market Estimates and Forecasts, 2020 - 2032
4.8 Anti-epileptics
4.8.1 Anti-epileptics Market Estimates and Forecasts, 2020 - 2032
4.9 Others
4.9.1 Others Market Estimates and Forecasts, 2020 - 2032
Chapter 5 Europe Branded Generics Market: Segment Analysis, by Application, 2020 - 2032
5.1 Europe Branded Generics Market: Application Movement Analysis
5.2 Oncology
5.2.1 Oncology Market Estimates and Forecast, 2020 - 2032
5.3 cardiovascular diseases
5.3.1 Cardiovascular Diseases Market Estimates and Forecast, 2020 - 2032
5.4 Neurological Diseases
5.4.1 Neurological Diseases Market Estimates and Forecast, 2020 - 2032
5.5 Acute and Chronic Pain
5.5.1 Acute and Chronic Pain Market Estimates and Forecast, 2020 - 2032
5.6 Gastrointestinal Diseases
5.6.1 Gastrointestinal Diseases Market Estimates and Forecast, 2020 - 2032
5.7 Dermatological Diseases
5.7.1 Dermatological Diseases Market Estimates and Forecast, 2020 - 2032
5.8 Others
5.8.1 Others Market Estimates and Forecast, 2020-2032
Chapter 6 Europe Branded Generics Market: Segment Analysis, by Route of Administration, 2020 - 2032
6.1 Europe Branded Generics Market: Route of Administration Movement Analysis
6.2 Topical
6.2.1 Topical Market Estimates and Forecast, 2020 - 2032
6.3 Oral
6.3.1 Oral Market Estimates and Forecast, 2020 - 2032
6.4 Parenteral
6.4.1 Parenteral Market Estimates and Forecast, 2020-2032
6.5 Others
6.5.1 Others Market Estimates and Forecast, 2020 - 2032
Chapter 7 Europe Branded Generics Market - Segment Analysis, By Distribution Channel, 2020 - 2032
7.1 Europe Branded Generics Market: Distribution Channel Movement Analysis
7.2 Hospital Pharmacy
7.2.1 Hospital Pharmacy Market Estimates and Forecast, 2020 - 2032
7.3 Retail Pharmacy
7.3.1 Retail Pharmacy Market Estimates and Forecast, 2020-2032
7.4 Online Pharmacy
7.4.1 Online Pharmacy Market Estimates and Forecast, 2020 - 2032
Chapter 8 Europe Branded Generics Market: Regional Estimates and Trend Analysis, by Drug Class, Application, Route of Administration, & Distribution Channel
8.1 Europe
8.1.1 SWOT Analysis:
8.1.1.1 Europe Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.2 Germany
8.1.2.1 Key Country Dynamics
8.1.2.2 Target Disease Prevalence
8.1.2.3 Competitive Scenario
8.1.2.4 Regulatory Framework
8.1.2.5 Reimbursement Scenario
8.1.2.6 Prescription and Dispensing Scenario
8.1.2.7 Germany Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.3 UK
8.1.3.1 Key Country Dynamics
8.1.3.2 Target Disease Prevalence
8.1.3.3 Competitive Scenario
8.1.3.4 Regulatory Framework
8.1.3.5 Reimbursement Scenario
8.1.3.6 UK Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.4 France
8.1.4.1 Key Country Dynamics
8.1.4.2 Target Disease Prevalence
8.1.4.3 Competitive Scenario
8.1.4.4 Regulatory Framework
8.1.4.5 Reimbursement Scenario
8.1.4.6 France Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.5 Italy
8.1.5.1 Key Country Dynamics
8.1.5.2 Target Disease Prevalence
8.1.5.3 Competitive Scenario
8.1.5.4 Regulatory Framework
8.1.5.5 Reimbursement Scenario
8.1.5.6 Italy Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.6 Spain
8.1.6.1 Key Country Dynamics
8.1.6.2 Target Disease Prevalence
8.1.6.3 Competitive Scenario
8.1.6.4 Regulatory Framework
8.1.6.5 Reimbursement Scenario
8.1.6.6 Spain Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.7 Russia
8.1.7.1 Key Country Dynamics
8.1.7.2 Target Disease Prevalence
8.1.7.3 Competitive Scenario
8.1.7.4 Regulatory Framework
8.1.7.5 Reimbursement Scenario
8.1.7.6 Russia Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.8 Denmark
8.1.8.1 Key Country Dynamics
8.1.8.2 Target Disease Prevalence
8.1.8.3 Competitive Scenario
8.1.8.4 Regulatory Framework
8.1.8.5 Reimbursement Scenario
8.1.8.6 Denmark Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.9 Sweden
8.1.9.1 Key Country Dynamics
8.1.9.2 Target Disease Prevalence
8.1.9.3 Competitive Scenario
8.1.9.4 Regulatory Framework
8.1.9.5 Reimbursement Scenario
8.1.9.6 Sweden Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.10 Norway
8.1.10.1 Key Country Dynamics
8.1.10.2 Target Disease Prevalence
8.1.10.3 Competitive Scenario
8.1.10.4 Regulatory Framework
8.1.10.5 Reimbursement Scenario
8.1.10.6 Norway Branded Generics Market Estimates and Forecasts, 2020 - 2032
8.1.11 Rest of Europe
Chapter 9 Europe Branded Generics Market: - Competitive Landscape
9.1 Recent Developments & Impact Analysis, by Key Market Participants
9.1.1 New Product Launch
9.1.2 Merger and Acquisition
9.1.3 Licensing Agreements
9.1.4 Conferences and Campaigns
9.2 Company Categorization
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 List of key distributors and channel partners
9.3.2 Key customers
9.4 Public Companies
9.4.1 Key company market share analysis, 2021
9.4.2 Company market position analysis
9.4.3 Heat map analysis
9.4.4 Competitive Dashboard Analysis
9.4.4.1 Market Differentiators
9.5 Private Companies
9.5.1 List of key emerging companies
9.5.2 Regional Network Map
9.6 Company Profiles
9.6.1 Teva Pharmaceutical Industries Ltd.
9.6.1.1 Company overview
9.6.1.2 Financial performance
9.6.1.3 Product benchmarking
9.6.1.4 Strategic initiatives
9.6.2 LUPIN
9.6.2.1 Company overview
9.6.2.2 Financial performance
9.6.2.3 Product benchmarking
9.6.2.4 Strategic initiatives
9.6.3 Sanofi
9.6.3.1 Company overview
9.6.3.2 Financial performance
9.6.3.3 Product benchmarking
9.6.3.4 Strategic initiatives
9.6.4 Sun Pharmaceutical Industries Ltd.
9.6.4.1 Company overview
9.6.4.2 Financial performance
9.6.4.3 Product benchmarking
9.6.4.4 Strategic initiatives
9.6.5 Dr. Reddy’s Laboratories Ltd.
9.6.5.1 Company Overview
9.6.5.2 Financial Performance
9.6.5.3 Product benchmarking
9.6.5.4 Strategic initiatives
9.6.6 Endo International plc
9.6.6.1 Company overview
9.6.6.2 Financial performance
9.6.6.3 Product benchmarking
9.6.6.4 Strategic initiatives
9.6.7 GlaxoSmithKline Plc
9.6.7.1 Company Overview
9.6.7.2 Financial Performance
9.6.7.3 Product Benchmarking
9.6.7.4 Strategic Initiatives
9.6.8 Wockhardt
9.6.8.1 Company overview
9.6.8.2 Financial Performance
9.6.8.3 Product benchmarking
9.6.8.4 Strategic initiatives
9.6.9 Viatris, Inc.
9.6.9.1 Company Overview
9.6.9.2 Financial Performance
9.6.9.3 Product Benchmarking
9.6.9.4 Strategic Initiatives
9.6.10 Apotex, Inc.
9.6.10.1 Company overview
9.6.10.2 Product benchmarking
9.6.10.3 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers